Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7059MR)

This product GTTS-WQ7059MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic retinopathy research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ7059MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12364MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA N63Ab
GTTS-WQ13877MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-1979
GTTS-WQ15851MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ2580MR IVTScrip™ mRNA-Anti-MPL, AMG 531(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 531
GTTS-WQ15945MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ633MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ10156MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LBR-101
GTTS-WQ14369MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW